Group One Trading
PTGX icon

Group One Trading’s Protagonist Therapeutics PTGX Stock Holding History

Group One Trading’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-70
Closed -$2.93K – 8225
2024
Q4 		$2.7K Buy
+70
New +$3.05K ﹤0.01% 6641
2024
Q3 		– Sell
-8,638
Closed -$349K – 7223
2024
Q2 		$299K Sell
8,638
-19,725
-70% -$578K ﹤0.01% 3050
2024
Q1 		$821K Buy
+28,363
New +$772K ﹤0.01% 2266
2023
Q1 		– Sell
-1,307
Closed -$21.9K – 7806
2022
Q4 		$14.3K Sell
1,307
-20,956
-94% -$177K ﹤0.01% 5829
2022
Q3 		$188K Sell
22,263
-21,651
-49% -$205K ﹤0.01% 4204
2022
Q2 		$347K Buy
43,914
+32,897
+299% +$398K ﹤0.01% 3768
2022
Q1 		$261K Buy
+11,017
New +$310K ﹤0.01% 4521
2021
Q4 		– Sell
-1,800
Closed -$56.9K – 8728
2021
Q3 		$32K Buy
+1,800
New +$76.7K ﹤0.01% 6882

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Group One Trading's PTGX Position: Q1 2025 in Review

Group One Trading sold out of Protagonist Therapeutics (PTGX) in Q1 2025, closing a stake of 70 shares — an estimated $2.93K sold.

Group One Trading first reported a position in PTGX in Q3 2021 and held it in 8 quarters. The position peaked at $821K in Q1 2024. 275 funds tracked by Wall St. Rank hold PTGX as of Q1 2025.

  • Group One Trading reported no remaining Protagonist Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Group One Trading sold 70 Protagonist Therapeutics shares in Q1 2025, an estimated $2.93K.
  • Group One Trading first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 8 quarters.
  • Group One Trading's Protagonist Therapeutics position peaked at $821K in Q1 2024.
  • 275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2025.

Based on Group One Trading's 13F filing for Q1 2025, filed 14 May 2025.